IL1B and metastatic malignant neoplasm: Additionally, a combination of therapies that target both upstream activators (e.g., IL-1β, ROS) and downstream NET formation mediators could enhance therapeutic outcomes, particularly in complex conditions such as autoimmune vasculitis or metastatic cancer [16,52].